BioBAY
a flagship biopharma industrial park whose tenant and partner base includes AstraZeneca, BeiGene, Innovent and other major China-based drug developers; it co-hosted the June 2026 "Future of Medicine" summit in Suzhou and continues to expand its cleanroom-equipped medical-device zone.
- Country
- China
industrial-park
cn
Coverage
| CN | EU | US | |
|---|---|---|---|
| finance-investment | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Venture studios & biotech incubators | finance-investment | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.